Cellular Responses to p53 Activation by Nutlin-3a
Cellular Responses to p53 Activation by Nutlin-3a
批准号:
8471662
负责人:
Carl G Maki
金额:
$28.38万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-13 至 2015-05-31
关键词:
ActinsAdverse effectsAneuploid CellsAneuploidyApoptosisAutomobile DrivingBiological AssayBreast Cancer CellCancer cell lineCell LineCellsChromosomesCisplatinCollectionCytoskeletal ModelingDNADNA DamageDNA biosynthesisDataDevelopmentDoseEpithelial CellsExcisionFamilyFocal AdhesionsG1 ArrestGenerationsGenomic InstabilityGlucocorticoid ReceptorGoalsGrantGrowthGuanosine Triphosphate PhosphohydrolasesHCT116 CellsHumanInvadedM cellMDM2 geneMYC geneMalignant NeoplasmsMammary glandMediatingMitosisNormal CellPathway interactionsPharmaceutical PreparationsPolyploid CellsProtein p53RU-486RadiationReceptor ActivationReportingResistanceSignal TransductionStressStress FibersTestingTherapeuticTherapeutic AgentsTissuesTumor Suppressor Proteinsabstractinganticancer researchbasecancer cellcancer therapycarcinogenesiscell growthcell motilitycell typeimmortalized cellin vivointerestkillingsmatrigelmigrationnutlin 3preventresponserhosmall moleculewound
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary / Abstract:
Wild-type p53 is a potent tumor suppressor that is activated by DNA damage and other stresses. There has
been considerable interest in restoring wild-type p53 function as a therapeutic strategy. This goal has led to
the development of the Nutlin-3 (Nutlin), a small molecule that activates wild-type p53 by blocking its
interaction with MDM2, the primary negative regulator of p53 activity in cells. Notably, Nutlin activates p53
through a non-genotoxic mechanism, and thus its use as a therapeutic agent may spare tissues of deleterious
side-effects associated with common DNA damaging drugs. Effective use of Nutlin requires that its effects on
cells be fully understood. We have examined the response of various p53 wild-type cell lines to transient
Nutlin treatment. We find that p53 activation by Nutlin can promote growth arrest or apoptosis in cells
dependent on activation of survival pathways, and we have identified a candidate survival factor that protects
cells from Nutlin-induced apoptosis. We also find that Nutlin has surprising effects on cytoskeletal organization
and control of DNA endoreduplication. The purpose of this grant is to determine the effects of Nutlin-mediated
p53 activation on these various cellular responses.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.2174/138161211795222603
发表时间:
2011
期刊:
Current pharmaceutical design
影响因子:
3.1
作者:
[Shen H, Maki CG]
通讯作者:
Maki CG
DOI:
10.18632/oncotarget.5218
发表时间:
2015-09-15
期刊:
Oncotarget
影响因子:
--
作者:
[Duan L, Perez RE, Davaadelger B, Dedkova EN, Blatter LA, Maki CG]
通讯作者:
Maki CG
DOI:
10.1038/onc.2011.185
发表时间:
2011-11-17
期刊:
ONCOGENE
影响因子:
8
作者:
[Aziz, M. H., Shen, H., Maki, C. G.]
通讯作者:
Maki, C. G.
DOI:
10.1016/j.canlet.2014.07.031
发表时间:
2014-10-28
期刊:
Cancer letters
影响因子:
9.7
作者:
[Duan L, Danzer B, Levenson VV, Maki CG]
通讯作者:
Maki CG
DOI:
10.1371/journal.pone.0059848
发表时间:
2013
期刊:
PloS one
影响因子:
3.7
作者:
[Shen H, Perez RE, Davaadelger B, Maki CG]
通讯作者:
Maki CG
A synthetic lethal approach for targeting p53 deficient triple negative breast cancer
-
批准号:10650026
-
项目类别:
-
资助金额:$22.16万
-
财政年份:2023
-
负责人:Carl G Maki
-
依托单位:
Targeting Prolyl Peptidases in Tamoxifen Resistant Breast Cancer
-
批准号:9461165
-
项目类别:
-
资助金额:$5.69万
-
财政年份:2017
-
负责人:Carl G Maki
-
依托单位:
Targeting Prolyl Peptidases in Tamoxifen Resistant Breast Cancer
-
批准号:9115348
-
项目类别:
-
资助金额:$35.46万
-
财政年份:2016
-
负责人:Carl G Maki
-
依托单位:
Targeting Prolyl Peptidases in Tamoxifen Resistant Breast Cancer
-
批准号:9253372
-
项目类别:
-
资助金额:$35.46万
-
财政年份:2016
-
负责人:Carl G Maki
-
依托单位:
Targeting Prolyl Peptidases in Tamoxifen Resistant Breast Cancer
-
批准号:9912119
-
项目类别:
-
资助金额:$35.46万
-
财政年份:2016
-
负责人:Carl G Maki
-
依托单位:
Identification and Targeting Therapy Resistant Osteosarcoma
-
批准号:8814732
-
项目类别:
-
资助金额:$21.52万
-
财政年份:2015
-
负责人:Carl G Maki
-
依托单位:
Modeling The Etiology of P53 Mutated Cancer Cells
-
批准号:8571884
-
项目类别:
-
资助金额:$21.52万
-
财政年份:2013
-
负责人:Carl G Maki
-
依托单位:
Modeling The Etiology of P53 Mutated Cancer Cells
-
批准号:8704904
-
项目类别:
-
资助金额:$16.37万
-
财政年份:2013
-
负责人:Carl G Maki
-
依托单位:
Cellular Responses to p53 Activation by Nutlin-3a
-
批准号:7735485
-
项目类别:
-
资助金额:$31.13万
-
财政年份:2009
-
负责人:Carl G Maki
-
依托单位:
Cellular Responses to p53 Activation by Nutlin-3a
-
批准号:8271293
-
项目类别:
-
资助金额:$30.19万
-
财政年份:2009
-
负责人:Carl G Maki
-
依托单位:
Cellular Responses to p53 Activation by Nutlin-3a
-
批准号:8073582
-
项目类别:
-
资助金额:$30.19万
-
财政年份:2009
-
负责人:Carl G Maki
-
依托单位:
Physical and Functional Interactions Between PML & MDM2
-
批准号:6811808
-
项目类别:
-
资助金额:$24.02万
-
财政年份:2004
-
负责人:Carl G Maki
-
依托单位:
Physical and Functional Interactions Between PML & MDM2
-
批准号:7425780
-
项目类别:
-
资助金额:$22.77万
-
财政年份:2004
-
负责人:Carl G Maki
-
依托单位:
Physical and Functional Interactions Between PML & MDM2
-
批准号:6930623
-
项目类别:
-
资助金额:$24.02万
-
财政年份:2004
-
负责人:Carl G Maki
-
依托单位:
Physical and Functional Interactions Between PML & MDM2
-
批准号:7263223
-
项目类别:
-
资助金额:$22.77万
-
财政年份:2004
-
负责人:Carl G Maki
-
依托单位:
Physical and Functional Interactions Between PML & MDM2
-
批准号:7105102
-
项目类别:
-
资助金额:$23.45万
-
财政年份:2004
-
负责人:Carl G Maki
-
依托单位:
UBIQUITINATION AND STABILITY OF P53 AND P73
-
批准号:6174039
-
项目类别:
-
资助金额:$23.59万
-
财政年份:1999
-
负责人:Carl G Maki
-
依托单位:
p53 localization in normal and human tumor cells
-
批准号:7117863
-
项目类别:
-
资助金额:$24.76万
-
财政年份:1999
-
负责人:Carl G Maki
-
依托单位:
p53 localization in normal and human tumor cells
-
批准号:6823880
-
项目类别:
-
资助金额:$24.85万
-
财政年份:1999
-
负责人:Carl G Maki
-
依托单位:
p53 localization in normal and human tumor cells
-
批准号:6946513
-
项目类别:
-
资助金额:$25.35万
-
财政年份:1999
-
负责人:Carl G Maki
-
依托单位:
海外基金